Philip James Wealth Mangement LLC Purchases 3,205 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Philip James Wealth Mangement LLC lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 43.0% during the 4th quarter, HoldingsChannel reports. The firm owned 10,659 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,205 shares during the period. Philip James Wealth Mangement LLC’s holdings in Jazz Pharmaceuticals were worth $1,313,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. boosted its holdings in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after acquiring an additional 172 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 49.8% in the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 206 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc boosted its holdings in Jazz Pharmaceuticals by 56.7% in the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on JAZZ. Needham & Company LLC reissued a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $130.00 to $170.00 in a report on Thursday. TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average price target of $180.33.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $133.96 on Monday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a 50-day simple moving average of $123.47 and a two-hundred day simple moving average of $117.27. The stock has a market cap of $8.10 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 0.92 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $138.27.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 5,053 shares of company stock worth $617,442 over the last quarter. 4.20% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.